Jacobs Levy Equity Management, Inc Iovance Biotherapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $5.61 Million - $9.48 Million	-1,045,893 Reduced 67.0%	515,035 $3.63 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $6.08 Million - $9.04 Million	1,099,468 Added 238.26%	1,560,928 $9.54 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $1.55 Million - $2.76 Million	276,063 Added 148.9%	461,460 $2.95 Million
Q3 2022 Nov 15, 2022	BUY	$9.53 - $13.11 $140,500 - $193,280	14,743 Added 8.64%	185,397 $1.78 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $1.09 Million - $3.13 Million	170,654 New	170,654 $1.88 Million

319

238M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.